Navigation Links
Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements
Date:2/13/2008

r extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C- IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1- 800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; legal matters, including the ultimate outcome of the FTC litigation or the amount of time it will take for the FTC litigation to be resolved; market prospects for its products; sales, adjusted net income and basic adjusted income per common share guidance; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalons 2007 Results Exceed Full Year Sales and Earnings Guidance
2. Cephalon General Counsel John E. Osborn to Resign Position
3. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
4. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
5. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
6. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Announces Strong Third Quarter Financial Results
9. Cephalon Quarterly Conference Call Invitation
10. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
11. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Food and natural product manufacturers, ... food alternatives that offer variety, as well as, ... market has numerous players operating in the marketplace ... Technology (VFT). VFT is a science-driven functional ... all tested to produce stable, effective and repeatable ...
(Date:7/31/2014)... (1912-1954), is famous for a number of breakthroughs, which ... he published a paper, which laid the foundation of ... computer algorithm. He next played a pivotal role in ... the German military codes, enabling the Allies to defeat ... late 1940,s he turned his attention to artificial intelligence ...
(Date:7/31/2014)... New York , July 31, 2014 ... by Transparency Market Research "Quantum Dots Market - Global ... - 2023," the market was valued at USD 88.5 ... 8,246.8 million by 2023, growing at a CAGR of ... full Quantum Dots Market Report at  http://www.transparencymarketresearch.com/quantum-dots.html ...
(Date:7/31/2014)... July 31, 2014 Research and Markets ... Genomics Market 2014-2018" report to their offering. ... is the study of the genetic material or genomes ... strong basis for the discovery and development of diagnostic ... or health conditions. Genomics is supported by three major ...
Breaking Biology Technology:Functional Ingredient Manufacturer – Vital Force Technology Infuses Raw Materials & Ingredients with Subtle Energy Formula 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 2A mathematical theory proposed by Alan Turing in 1952 can explain the formation of fingers 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 2Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 3Global Quantum Dots Market is Expected to Reach USD 8,246.8 Million in 2023: Transparency Market Research 4Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... Boston College has been awarded a $1 million grant ... of university researchers developing a new microscope that uses ... and macroscopic matter with significantly improved clarity. The ... new class of microscopes known as "superlenses," which function ...
... 3, 2011 Ron Van Beek, president and CEO ... Synacore Digestive Support for dogs and cats, available exclusively ... synbiotic digestive support supplement containing both probiotics and prebiotics ... microflora in a dog,s or cat,s GI tract.  Van ...
... 3, 2011 Genomic Health, Inc. (Nasdaq: ... successfully surveyed expression of the whole human transcriptome ... Inc., to test hypotheses for biomarker discovery in ... study identified hundreds of coding and non-coding transcripts ...
Cached Biology Technology:Boston College receives W.M. Keck Foundation funding for nanoscale optical microscope 2Van Beek Natural Science Announces New Synacore Digestive Support Product 2Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue 2Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue 3Genomic Health Announces Results from Biomarker Discovery Program Utilizing Next-Generation Sequencing to Compare Normal and Tumor Breast Tissue 4
(Date:7/31/2014)... who studied 100 twin pairs have identified a gene mutation ... than six hours of sleep per night. The genetic ... of sleep deprivation. , Results show that a participant with ... an average nightly sleep duration of only five hours, which ... who slept for about six hours and five minutes per ...
(Date:7/31/2014)... team of scientists from Spain, France, and the ... that is the oldest definitive member of the ... amber. The discovery and description were made possible ... synchrotron imaging technique, which allows the detailed study ... new species is described in the journal ...
(Date:7/31/2014)... alters how the brain processes speech, potentially increasing ... neuroscientists at The University of Texas at Dallas. ... Ear and Hearing , researchers demonstrated for ... the brain,s recognition of speech sounds. , Noise-induced ... population, affecting an estimated 15 percent of Americans ...
Breaking Biology News(10 mins):Study of twins discovers gene mutation linked to short sleep duration 2UT Dallas study reveals effect of loud noises on brain 2
... Our brains, it turns out, are eco-friendly. A study published ... Venkatesh Murthy and Jakob Sorensen reveals that our brains have ... cells generate and propagate nerve impulses, or action potentials, by ... and out of the cells. Re-establishing the ion equilibrium after ...
... MADISON, WI, OCTOBER 12, 2009 Areas of ... and recreational (not grazing) purposes, i.e. "urban grasslands" are ... are over 150,000 km2of urban grasslands in the U.S. ... about nutrient runoff to streams, lakes, and estuaries and ...
... 13 CareFusion Corporation (NYSE: CFN ), a new ... the EnVe(TM) ventilator - a high-performance critical care ventilator for ... ventilator is 70-80 pounds lighter than other intensive care ventilators ... help hospitals increase the quality of patient care and decrease ...
Cached Biology News:Nitrogen mysteries in urban grasslands 2Nitrogen mysteries in urban grasslands 3CareFusion Launches EnVe(TM) Ventilator: 10-Pound High-Performance Critical Care Ventilator 2CareFusion Launches EnVe(TM) Ventilator: 10-Pound High-Performance Critical Care Ventilator 3
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
Agarose, Biotechnology grade, 500g...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
... c-Jun proto-oncogene was first identified as the cellular ... Jun B and Jun D have been shown ... C-terminal regions, which are involved in dimerization and ... involved in transcriptional activation, diverge. ...
Biology Products: